We’re committed to our mission of finding new treatments that may help improve the lives of people with cancer. We perform these trials to see if they can help prevent or treat cancer.
For patients with hormone receptor-positive breast cancer
There are three different receptors that are commonly found in breast cancer cells: the oestrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). When the hormones oestrogen and progesterone attach to their receptors, they are activated and fuel cancer growth. Active HER2 also fuels cancer growth. When any of these receptors are present on the cell, non-chemotherapy treatments that block these receptors, such as hormone therapy or HER2-targeted therapy, work either alone or in combination with chemotherapy to kill cancer cells or slow down their growth.
For patients with triple-negative breast cancer (TNBC)
Triple-negative breast cancer represents 10% to 15% of all breast cancers. A TNBC diagnosis means that the cancer cells have tested negative for the 3 different receptors that are commonly found on breast cancer cells: the oestrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2).
There is a lot to consider when deciding whether to participate in a clinical trial. Any clinical trial includes risks which the study doctor will review with you. Make sure you understand the risks before participating. Information populated in the search results comes from an external source.
